Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab as adjuvant therapy after nephrectomy in high‑risk clear cell renal carcinoma
ChiCTR2400092716Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in clear cell renal cell carcinoma (ccRCC), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: 2-year disease-free survival rate. Started Nov 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2400092716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092716.